AI Article Synopsis

  • RSV is a common virus that leads to many hospitalizations in kids, and new prevention methods are essential to reduce this impact.
  • In 2023, the FDA approved two preventive treatments: a maternal vaccine (Abrysvo) and a monoclonal antibody (Beyfortus), both showing effectiveness in reducing severe respiratory infections in young patients.
  • While the expansion of RSV prevention options is promising, ongoing clinical trials must assess both immediate and long-term safety risks associated with these new treatments.

Article Abstract

Purpose Of Review: Respiratory syncytial virus (RSV) is a ubiquitous virus and the leading cause of pediatric hospitalization in the United States. Prevention strategies are key for reducing the burden of RSV. Several new agents aimed at preventing RSV in infants and children were FDA-approved in 2023, and many more are in the development pipeline. This review highlights new developments in RSV prevention in pediatric patients and the important safety considerations for clinical trials.

Recent Findings: Two new preventive therapies were FDA approved in 2023; a maternal vaccine (Abrysvo) and a mAb (Beyfortus) have both demonstrated reduction in medically attended lower respiratory tract infections in infants and children. Evaluation of ongoing clinical trials demonstrates that the field is expanding further to include direct immunization of infants and children utilizing a variety of delivery modalities. While these developments present the optimistic prospect of RSV prevention in a range of ages, acute and long-term risks must be carefully evaluated.

Summary: Prevention of RSV is more accessible than ever, but careful consideration must be given to risks associated with new and developing prevention strategies. Rigor of clinical trials including longitudinal outcomes of agents in development and postmarketing surveillance of newly approved therapies will be of paramount importance to ensure long-term safety of new RSV prevention strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11189640PMC
http://dx.doi.org/10.1097/MOP.0000000000001336DOI Listing

Publication Analysis

Top Keywords

prevention strategies
12
infants children
12
rsv prevention
12
respiratory syncytial
8
syncytial virus
8
clinical trials
8
rsv
7
prevention
6
advances prevention
4
prevention respiratory
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!